2024-10-23 15:16:59
Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH
Corporate/ 2023-07-24
Ascletis Announces Dosing of the First P...

-- ASC41 is ranking first in China and third in the world in terms of clinical progress as a thyroid hormone receptor β (THRβ) agonist dru...

ASTRAZENECA, First Organization in Egypt receiving Best place to work for Millennials Award
Health/ 2023-07-22
ASTRAZENECA, First Organization in Egypt...

CAIRO,Oct. 5,2022-- AstraZeneca Egypt,was recently certified as a Best Place to Work for Millennials marking it the first organization in Eg...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release